• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>ZymoGenetics

ZymoGenetics

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022 - Research and Markets

    Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022 - Research and Markets

  2. International Equity Commentary – December 2013

    ZymoGenetics has filed for approval of its first independently owned drug.

©2017 Morningstar Advisor. All right reserved.